All In Biotech

NDA 017607 · Otsuka Icu Medcl

Dextrose 5% and Sodium Chloride 0.45% In Plastic Container

Dextrose, Sodium Chloride · Injection

Last checked: Nov 19, 2026Latest source record: Sep 8, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1975

Aug 13, 1975

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3,797

712 Phase 3, 359 recruiting

FAERS reports

167

157 serious, 58 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2025.

INDICATIONS AND USAGE Intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 13, 1975 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER · DEXTROSE 5GM/100ML; SODIUM CHLORIDE 450MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.

All 3,797 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting40
  • nausea34
  • hyponatraemia28
  • sepsis28
  • ascites27
  • constipation27
  • abdominal distension26
  • abdominal pain26
  • off label use26
  • general physical health deterioration25
  • anaemia24
  • appendicitis24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20071
20081
20101
20122
20133
20144
201514
20169
20176
20189
20196
202012
202112
202225
202320
202423
20257
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,414 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.